Active ingredientEnsifentrineCat. No. P-E056-001CAS 1884461-72-6Family · Pharmaceutical analytical standards
Ensifentrine
An inhaled inhibitor of the phosphodiesterases PDE3 and PDE4, combining a bronchodilator effect with an anti-inflammatory one; approved in the United States in 2024 for maintenance treatment of COPD. This family brings together the active ingredient, labelled standards and nitrosamines.
Did you know?It belongs to a family of molecules devised by Sir David Jack, the Scottish pharmacologist whose team had also developed salbutamol, in 1966.
Go to the active ingredient →Active ingredientEnsifentrineCat. No. P-E056-001CAS 1884461-72-6
Isotopically labelledEnsifentrine-d6Cat. No. P-E056-002
Isotopically labelledN-Nitroso Ensifentrine-d6Cat. No. P-E056-003
NitrosamineN-Nitroso EnsifentrineCat. No. P-E056-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.